The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics

A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma

(2013) J. F. Grippo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Telaprevir: Clinical Pharmacokinetics, Pharmacodynamics, and Drug–Drug Interactions

(2013) Tony K. L. Kiang et al.   CLINICAL PHARMACOKINETICS

Oral bioavailability of ospemifene improves with food intake

(2013) Pasi Koskimies et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Improved Human Bioavailability of Vemurafenib, a Practically Insoluble Drug, Using an Amorphous Polymer-Stabilized Solid Dispersion Prepared by a Solvent-Controlled Coprecipitation Process

(2012) Navnit Shah et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE